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Abstract 
We introduce a combination of existing and novel approaches to the assessment and prediction 
of particle properties intrinsic to the formulation and manufacture of pharmaceuticals. 
Naturally following on from established solid form informatics methods, we return to the drug 
lamotrigine, re-evaluating its context in the Cambridge Structural Database (CSD). We then 
apply predictive digital design tools built around the CSD-System suite of software, including 
Synthonic Engineering methods which focus on intermolecular interaction energies, to analyse 
and understand important particle properties and their effects on several key stages of 
pharmaceutical manufacturing. We present a new, robust workflow that brings these 
approaches together to build on the knowledge gained from each step and explain how this 
knowledge can be combined to provide resolutions at decision points encountered during 
formulation design and manufacturing processes. 
Introduction 
The attrition rate in pharmaceutical development is notoriously high, with as few as one in 
ten thousand candidate active pharmaceutical ingredients (APIs) realised as a marketed drug 
product.1 Many of these failures are associated with safety and efficacy problems, although a 
significant proportion of new drug applications fail due to manufacturing factors.2,3  
The interest in how computational approaches can provide insight into pharmaceutical 
development and manufacturing has grown considerably over the last two decades, especially 
following high-profile product failures such as ritonavir4 and rotigotine.5 Various approaches 
have resulted in the routine use of multi-scale molecular and data-driven modelling of 
properties such as polymorph stability,6–8 solubility9,10 and crystal morphology.11–14 
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In 2011, to celebrate the addition of the 500,000th entry into the CSD,15 the paper “One in 
half a million: a solid form informatics study of a pharmaceutical crystal structure” was 
published.16 In that study, the 500,000th entry into the CSD, an antiepileptic drug known as 
lamotrigine,17 was used to highlight the state of the art of the field of solid form informatics 
and to establish a solid form risk assessment protocol that is widely used within the 
pharmaceutical industry,18–20 and extensively used by the CCDC’s Crystal Form Consortium 
(CFC).21 
Although a good understanding of solid form properties exists, partly due to the availability 
of tactile informatics tools, a molecular level understanding of the relationship between particle 
and surface properties and manufacturability is less developed. Molecular modelling of the 
intermolecular interactions, or “synthons”, in the bulk and at the surface of a crystalline particle 
has led to the prediction of properties such as morphology,22–25 surface energy,26 and particle 
cohesivity/adhesivity.27 The wider use of these methods in a tactile way28 could lead to a deeper 
understanding of the molecular mechanisms which lead to problematic particulate properties, 
such as poor flowability, agglomeration and “fines” production, which can cause significant 
problems during drug product manufacture. 
As we now approach the 1,000,000th entry in the CSD, we revisit the structure of lamotrigine 
to both reassess its solid form in the context of nearly one million crystal structures and to 
highlight the advances made in analyses that provide information on particulate properties, 
addressing the next stage of the pharmaceutical product design and manufacturing pipeline. 
These tools are now being integrated into experimental workflows that can enhance our 
understanding of particle attributes and mechanical properties, enabling the link between form, 
performance and manufacturability to be made clearer. 
The Advanced Digital Design of Pharmaceutical Therapeutics (ADDoPT) project29, a 
collaborative endeavour between pharmaceutical companies, solution providers and academia, 
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seeks to bring the concept of “digital design” to the formulation design and manufacturing 
stages of the pharmaceutical supply chain. Here, we present a combined effort between several 
ADDoPT partners to establish a comprehensive workflow that naturally follows on from solid 
form informatics in order to streamline processes and anticipate potential bottlenecks in 
delivering drugs faster. 
 
Lamotrigine – A model drug? 
The antiepileptic drug lamotrigine (often marketed as Lamictal) was first developed by 
Wellcome Laboratories30 and now has relatively well understood physical properties. 
Lamotrigine falls into the category of Biopharmaceutical Classification System (BCS) Class-
II,31 meaning that it has low aqueous solubility but high permeability.32 Lamotrigine exhibits a 
far greater solubility in non-aqueous solvents and its solubility is significantly improved in 
solvent mixtures.33,34 
Chemically and structurally, it was established in the previous study that lamotrigine is a 
typical drug molecule.16 Consequently, the application of knowledge derived from all the 
structures from the CSD provides a powerful framework for better understanding a given 
material’s solid form. More recent work further exploring the chemical and crystallographic 
space inhabited by drugs and non-drugs in the CSD35 shows that the values of several 
descriptors for lamotrigine are typical of a marketed small molecule drug, although the number 
of acceptors in the molecule is slightly higher than average (Figure 1). Repeating the solid 
form informatics calculations in the context of nearly 1,000,000 crystal structures shows that 
the anhydrous form of lamotrigine (CSD Refcode EFEMUX) has features that are 
characteristic of a stable solid form – a “usual” conformation, based on geometric distributions 
from the CSD,36 is observed and the arrangement of intermolecular interactions in the crystal 
structure is as would be expected.  
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Figure 1. Comparison of selected molecular descriptors of lamotrigine relative to the 
distributions of approved drugs in the CSD Drug Subset. 
While the solid form of lamotrigine is now well understood to be stable and efficacious, the 
behaviour of the particulate material during formulation and drug product manufacture is much 
further from the ideal. Through correspondence with GlaxoSmithKline and a thorough review 
of available literature, we have gained some insight into the manufacturing and formulation of 
the final product and acquired some understanding of the issues encountered therein. 
Formulations of lamotrigine are fairly typical, and generally consist of wet granulated 
lamotrigine in combination with lactose monohydrate, magnesium stearate, microcrystalline 
cellulose and sodium starch glycolate.37 Due to lamotrigine’s low solubility in aqueous media, 
the API is typically micronized to 3-5 たm. Anhydrous lamotrigine is known to have poor flow 
properties, and is sometimes prone to “capping” upon tableting due to low compressibility of 
the API.38 
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Properties such as poor powder flow and poor compressibility seen for lamotrigine often 
pose a challenge in the production of a formulated medicine. When understood holistically, 
these properties can be used to assess the feasibility of different processing routes through the 
concept of the Manufacturing Classification System (MCS).2,39 Identifying these factors 
through computational and informatics approaches in advance of manufacturing processes 
could cut the time and costs involved in bringing a drug product to market by reducing resource 
intensive experimental testing.40 Additionally, by having a full description of both the solid 
form and particle form as a companion to experimental measurements, any potential problems 
might be rectified before they ever occur. 
 
The “Particle Informatics” workflow 
In this work we propose how novel and existing digital design tools can be organised into a 
workflow to better understand several stages in the formulation and manufacturing pipeline of 
small molecule pharmaceuticals. 
 
Figure 2. Steps involved in the proposed "Particle Informatics" workflow. The output from 
each step flows into the next to provide a full picture of the particle properties. 
Taking each step of the workflow in turn, and comparing the insights gained with targeted 
experimental measurements, a thorough appreciation of the particle properties of a material can 
be gained. With this knowledge, key decisions made during pharmaceutical processes are better 
informed, avoiding potential bottlenecks during formulation design and manufacturing and 
enabling drugs to be delivered faster. 
7 
 
What follows is an explanation of each step in the “Particle Informatics” workflow using 
lamotrigine as an example drug product. The relevance, digital design tools used, and 
knowledge gained are outlined for each stage with each building on the last to provide a 
comprehensive understanding of particle properties and their contributions to pharmaceutical 
formulation and manufacturing processes. 
 
Intermolecular interactions and energetic analysis 
The solid-state properties of a material are inevitably dictated by the nature of the 
intermolecular interactions present. Gaining insight into the nature, chemistry and context of 
these interactions within the bulk of the particle (defining the intrinsic synthons) can shed key 
insight into how a solid might behave. Highly anisotropic interactions can have a marked effect 
on bulk properties, such as mechanical properties, but may also affect crystal growth 
morphology and surface behaviour. The orientation of these intermolecular interactions 
relative to the particle’s surfaces (defining the extrinsic synthons) can also pose issues in 
formulation, particularly for highly anisotropic particles. Weak interactions normal to the long 
axis of a needle-like crystal, for instance, may result in breakage and the creation of “fines”. 
An assessment of the strength and directionality of the intermolecular interactions in a crystal 
structure can be made by performing a lattice energy calculation. Here, we have performed this 
using HABIT9841,42 with the Dreiding forcefield.43 This approach not only gives the individual 
intermolecular interaction energies and an estimate of the total lattice energy, but provides a 
breakdown of the energy into the contributing hydrogen bonding, van der Waals dispersion 
and electrostatic terms. 
 
Compound Molecular weight (g mol-1) Calculated lattice energy 
(kcal mol-1) 
acetanilide 135.2 -23.9 
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p-aminobenzoic acid 137.1 -24.5 
paracetamol 151.2 -28.2 
phenacetin 179.2 -29.1 
ibuprofen 206.3 -28.9 
mefenamic acid 241.3 -31.7 
lamotrigine 256.1 -32.3 
tolfenamic acid 261.7 -30.0 
flufenamic acid 281.2 -28.5 
niflumic acid 282.2 -31.1 
diclofenac 296.1 -27.7 
DPC-963 316.2 -29.0 
Table 1. Comparison of calculated lattice energies and molecular weights for lamotrigine and 
some other small molecule pharmaceuticals 
Table 1 shows that the lattice energy calculated for lamotrigine, relative to its molecular 
weight, compares favourably with the general trend of values calculated for other small 
molecule pharmaceuticals. The more negative lattice energy observed for lamotrigine may 
arise from its larger size relative to other small molecule drugs but may also indicate that it 
forms several strong interactions in the solid state. This is evidenced by observing how the 
lattice energy is partitioned over the functional groups of the molecule. 
 
Figure 3. (Left) The percentage contributions to the total lattice energy of lamotrigine from 
each functional group. (Right) The calculated lattice energy of lamotrigine broken down into 
contributing terms. 
ヲヵくΒХ 
ンヴくΓХ 
ΒくヶХ 
ヱヵくヵХ 
ヱヵくンХ 
Lattice energy: -32.3 kcal/mol 
H-bond energy: -9.9 kcal/mol 
vdW dispersion: -20.9 kcal/mol 
Electrostatic energy: -1.5 kcal/mol 
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Figure 3Figure 3 indicates that, in terms of the atom-atom pairwise energy summation, the 
lattice energy is partitioned evenly between the moieties that comprise the molecule, with the 
more polar amine and chlorine groups making similar contributions to the lattice energy. The 
less polar ring moieties both make considerable contributions to the total lattice energy, with 
van der Waals interactions making up over 60% of the total energy. 
The individual intermolecular interaction motifs, or “synthons”, can be examined, and their 
relative energies and orientations can be used to understand the interactions in the crystal 
structure. 
The most common source of anisotropy in a crystal structure comes from the dimensionality 
of any hydrogen bond networks present.44,45 An automatic assignment of the hydrogen bond 
network dimensionality, based on the relative change in the dimensions of a bounding box 
surrounding the network as it expands,46 can be used to assess the isotropy of these interactions. 
Anhydrous lamotrigine displays a 3-dimensional hydrogen bonding network, extending in all 
dimensions. 
 
Figure 4. The strongest pairwise intermolecular synthons calculated from the bulk structure of 
lamotrigine and their energies. Hydrogen bonds are indicated by dashed lines. 
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As Figure 4 shows, the strongest synthon (A) in the lamotrigine crystal structure is a dimeric 
hydrogen bonding interaction between one of the amine groups and one of the triazine nitrogen 
atoms. These dimers are subsequently linked through a weaker hydrogen bond between the 
same amine group and the remaining triazine nitrogen atoms (synthon E) to create sheets of 
lamotrigine molecules. Another hydrogen bond between the other amine group and one of the 
chlorine atoms (synthon B) bridges these sheets, creating the three-dimensional hydrogen 
bonding network. 
Two important dispersion interactions are also present in the structure of lamotrigine. 
Synthon C is a stacking interaction that occurs between dichlorobenzene rings bridging the 
hydrogen bonded sheets made by synthons A and E. Synthon D arises due to a favourable 
“interlocking” of molecules, facilitated by the conformation that they adopt in the solid state, 
and sits within the hydrogen bonded sheets. 
The relative strengths and orientations of the key synthons in lamotrigine indicates a broadly 
isotropic, three-dimensional arrangement of intermolecular interactions. Consequently, this 
suggests the likely formation of equant particle morphologies. 
Mechanical properties prediction and analysis 
The mechanical properties of individual pharmaceutical crystallites are strongly correlated 
with the overall formulation performance and processability.47–49 In particular, the plasticity or 
compressibility of the API has been shown to have a marked effect on the quality of tablets, 
particularly those with high drug loading.50,51 Materials with a low elastic recovery tend to 
produce stronger, more resilient tablets, and this behaviour is intrinsically linked to the 
arrangement of molecules in its structure and the orientation and strength of the forces between 
them.52,53 
In crystals, the presence of a layered structure containing planes of molecules that are free to 
slide over each other has been consistently identified as a likely source of dislocation defect 
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formation in response to mechanical stress.53,54 This, in turn, has been attributed to low elastic 
recovery and consequently improved tabletability. By scanning for the least interdigitated plane 
through a crystal structure, a prediction of the likely source of dislocation upon compression 
can be made.46 When combined with additional descriptors, such as the spacing between planes 
or the dimensionality of any hydrogen bonding in the structure, the likely ease of dislocation, 
and consequently the likelihood of plastic deformation, can be assessed purely from the 
topological arrangement of molecules. An overarching structure for the prediction of 
mechanical properties has been summarised by Olusanmi et al.55 
As discussed previously, lamotrigine is known to exhibit problems during tabletting – most 
notably low compressibility and “capping”, the result of rapid elastic recovery upon removal 
of the tablet punch which leads to fracturing and lamination of the tablet. In the crystal structure 
of lamotrigine, the least interdigitated plane is identified as hkl = 2, 0, -2 with a separation of 
0.86 Å (based on atom centroid-centroid distances). 
 
 
Figure 5. The (2, 0, -2) planes in the crystal structure of lamotrigine, identified as the least 
interdigitated. 
While Figure 5 shows that the (2, 0, -2) planes are not interdigitated, and therefore have the 
potential to slip, the analysis described above indicates that they are bridged by multiple strong 
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N-H…N hydrogen bonds (synthon A), as well as aromatic stacking interactions (synthon C) 
which will add rigidity across the interface and reduce any slip propensity. Additionally, the 
relatively small d-spacing of 6.28 Å between planes is indicative of low plasticity. These two 
descriptors combined indicate that lamotrigine is at best moderately plastic, however when 
combined with a high lattice energy, 3-dimensional hydrogen bonding network and the 
isotropic nature of the remaining intermolecular interactions this assessment indicates that the 
material is unlikely to exhibit good plastic deformation under compression. 
Combining this topological approach with a knowledge of the strength and orientation of 
intermolecular interactions in a crystal structure provides key insights into the bulk properties 
of a material. Through investigating these features as early as possible during pharmaceutical 
development, potential bottlenecks that may arise in processes that depend on these properties, 
such as tableting, can be identified and anticipated. 
 
Particle morphology calculation and analysis 
While the bulk powder of an API will never be composed of perfectly formed single crystals 
of uniform morphology, having an understanding of the dominant faces and potential aspect 
ratio of the crystals can provide a great deal of information about potential downstream particle 
behaviour, particularly in terms of flow, sticking and tabletability.56,57 In the case of 
lamotrigine, the experimentally determined crystal morphology of the bulk solid is found to be 
prismatic (Figure 6, left). However, in the presence of 1.2% 2,3-dichlorobenzoic acid (an 
impurity resulting from the chemical synthesis), the crystallites are found to be far smaller, 
more anisotropic in shape and to form agglomerates (Figure 6, right).38 
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Figure 6. Experimental morphologies of lamotrigine without (left) and with (right) the 
presence of the impurity 2,3-dichlorobenzoic acid 
An established means of predicting crystal morphologies is the energy of attachment 
method.13 This uses some computational method to estimate the binding strength of molecules 
in different slices through a crystal structure, and equates the relative growth rate of a face to 
this strength of binding. Making use of the intermolecular interaction energies calculated 
above, we have used HABIT to predict the attachment energy crystal morphology of 
lamotrigine (Figure 7). 
 
Figure 7. Attachment energy crystal morphology of lamotrigine calculated using the Dreiding 
forcefield. 
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The energy of attachment morphology of lamotrigine is found to be quite equant, consistent 
with the three-dimensional orientation of the synthons within the bulk structure described 
previously. This results in a prismatic crystal shape, which seems to qualitatively agree with 
the observed morphology of lamotrigine in the absence of an impurity. The external 
morphology is found to be dominated by the {200}, {002}, {110}, {11-1} and {20-2} faces. 
 
Surface energy and topology analysis 
Depending on the morphology, the surface energies, topologies and chemistry exposed on 
each crystal surface can vary enormously. Gaining an insight into this variation for a specific 
system is therefore a key factor in understanding the behaviour of a solid form during 
formulation, and assessing any risks posed by batch to batch variation. Furthermore, since each 
crystal surface will interact differently with air, moisture, tooling, solvents and excipients, for 
instance, understanding the nature of the dominant faces of a particle is critical in understanding 
the behaviour of the solid during manufacturing processes. 
 
Face 
Surface 
Energy 
(mJ m-2) 
Anisotropy 
Factor (%) 
Contributing Terms (%) 
van der Waals 
H-
Bonding 
Electrostatic 
{200} 82.3 57 60 30 2 
{110} 80.3 53 51 37 4 
{11-1} 76.7 51 49 36 6 
{20-2} 69.3 50 56 32 5 
{002} 66.1 49 47 40 5 
{31-1} 60.7 46 61 27 4 
Total* 75.8     
Table 2. Individual surface energies and anisotropy factors for the attachment energy predicted 
morphology faces of lamotrigine. Also shown are the total particle surface energy, and the 
percentage contributions of different energy terms to the growth of these surface. *The total 
surface energy was calculated as the summation of the surface energy for each face multiplied 
by its fractional surface area. 
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The surface energies of the individual faces were obtained during the attachment energy 
calculation outlined above. For each surface, a single d-spacing of each face is cycled through 
in 0.1 d-spacing steps, and slice and attachment energies are calculated for the surface 
termination at each step. The termination with the lowest energy in each case provides the 
reported stable surface. For lamotrigine these surface energies have been normalised to their 
predicted relative surface areas in the crystal morphology (Table 2). The particle surface 
energy calculated for lamotrigine is higher than that of, for example, ibuprofen,58 although this 
may be expected due to the greater lattice energy calculated for lamotrigine. In contrast to 
crystal morphologies with particularly large individual surfaces, such as plates or needles 
where the dominant face is likely to be very low in energy,59 the equant shape of this crystal 
suggests that individual surfaces will have comparable surface energies. 
The anisotropy factors (defined as the slice energy divided by the total lattice energy) 
calculated for the individual habit surfaces (Table 2) were found to be very similar, with the 
large {200} faces 57% satisfied and the small {31-1} faces 46% satisfied. These faces are also 
determined to have the greatest van der Waals contribution to their surface energy. This is again 
consistent with the isotropic shape of the crystal. The contributions of the different energy 
terms reveal that the {110}, {11-1} and {002} faces are found to have the greatest contribution 
from H-bonding interactions, consistent with the orientation of hydrogen bonds in the crystal 
structure. Both the {110} and {11-1} surfaces are major habit faces, indicating that lamotrigine 
crystals are likely to interact with more polar, hydrogen bonding species. 
To further rationalise the particle properties, an understanding of the surface topology, and 
the chemistry presented on these surfaces, is required. The topology of a crystal surface is 
important, as rough faces typically have a lower barrier for surface adsorption than closely-
packed smooth planes.60 A knowledge of the position of certain functional groups relative to 
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topological features such as pockets and channels is also useful to enable the prediction of 
surface effects. Utilising the CSD Python API, we can generate a simple, standardised 
visualisation of the crystal surfaces present on a given morphology from which numerous 
topological and chemical features can be identified. 
 
 
 
Figure 8. (Top left) The {1, 1, 0} face of lamotrigine displaying the chemistry of the surface. 
Nitrogen atoms are blue, chlorine atoms are green, carbon atoms are grey and hydrogen atoms 
are white. (Top right) The contour map of the corresponding van der Waals surface. Yellow 
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regions indicate displacement out of the plane of the page, and blue/green regions indicate 
displacement into the page. (Bottom) The topological van der Waals surface. All images show 
an 84 Å x 84 Å area. 
Face Donor Density Acceptor Density Aromatic Density Roughness (Å) 
{200} 1.74 3.48 13.6 3.23 
{110} 1.90 2.50 10.3 6.53 
{1-11} 1.10 2.90 9.6 3.50 
{20-2} 1.20 3.50 16.4 2.60 
{002} 1.20 3.09 15.6 1.97 
Table 3. Surface descriptors for the major faces of lamotrigine. Donor and acceptor densities 
are given as atoms per unit area of the surface. The aromatic density is given by the number of 
aromatic bonds per unit area. Roughness is measured by the distance from the highest contour 
peak to the lowest valley along the Z-axis. 
Figure 8 and Table 3 show that the {110} face of lamotrigine contains several exposed 
amine groups, consistent with the relatively high hydrogen bonding contribution to the surface 
energy described above. While some chlorine atoms are exposed, the majority sit slightly 
further from the surface, as do the aromatic rings, consistent with the lower van der Waals 
contribution to the {110} face. Table 3 also shows that the {110} faces are particularly rough, 
and the contour map (Figure 8, right) shows that peaks and valleys run across them. Figures 
relating to other major surfaces of lamotrigine are given in the Supplementary Material. 
Combining surface energies along with an assessment of the topological and chemical nature 
of those surfaces allows for an assessment of their likely behaviour as particles, and an 
understanding of how they might interact with other particles and surfaces. For instance, the 
high-energy {110} face, with exposed functional groups and a relatively high roughness, is 
indicative of a surface that might readily interact with many other species during formulation 
and manufacturing.  
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Analysis of interactions at surfaces 
With knowledge of the character of the likely exposed surfaces of particles, it is advantageous 
to be able to model how various solvents, excipients and impurities might interact with these 
surfaces during manufacturing processes. Utilising systematic search methods,61 we have 
examined the adsorption of various relevant molecules to the major habit faces of lamotrigine. 
Using the same computational methods outlined above for the calculation of morphologies 
and surface energies, the interactions of the solvents water and toluene, the excipients 
microcrystalline cellulose (MCC) and lactose monohydrate, the identified impurity 2,3-
dichlorobenzoic acid, and of lamotrigine with itself, have been investigated. 
 
Figure 9. The average energy of the top 100 probe-surface interactions for the major facets of 
lamotrigine for water, toluene, dichlorobenzoic acid (impurity), lamotrigine, microcrystalline 
cellulose (MCC) and lactose monohydrate (Lactose). The MCC probe was modelled as a single 
repeat unit of the polymer and the lactose monohydrate probe as a single lactose molecule and 
a single water molecule. 
Figure 9 shows the average energies of the top 100 interactions of the various probe 
molecules studied on each of the surfaces. The most favourable surfaces for interaction in all 
19 
 
cases are for the {110} form, consistent with observations made above regarding these faces’ 
high energy and roughness. Water, toluene, and the impurity 2,3-dichlorobenzoic acid show 
similar interaction trends, indicating a relatively consistent level of reactivity for each 
lamotrigine face. 
Comparing the interactions for lamotrigine with itself and 2,3-dichlorobenzoic acid, it is 
apparent that the impurity shows competitive interaction energies on several surfaces. 
Particularly in the case of the {110} faces, which show increased exposure of amine groups, a 
multi-component Hydrogen Bond Propensity calculation62 indicates several competitive 
probable hydrogen bond interactions. As shown in Figure 6, lamotrigine crystals grown in the 
presence of even a modest amount of the 2,3-dichlorobenzoic acid impurity are much smaller 
and more irregular in shape than those grown in the absence of the impurity. This indicates that 
either the impurity depresses the cloud point and forces nucleation to occur at a much higher 
supersaturation, or that the impurity simply depresses crystal growth at key faces. The 
competing interactions of 2,3-dichlorobenzoic acid with lamotrigine are consistent with both 
effects.  
It is interesting to note the relatively weak interactions of water with all major faces, 
consistent with the low aqueous solubility observed for lamotrigine. The interactions of the 
excipients (microcrystalline cellulose and lactose monohydrate) are found to be greater than 
those of the drug with itself. The low anisotropy factors of all the faces indicate that there are 
strong synthons broken at each surface, resulting in these surfaces being likely to form strong 
interactions with the surrounding environment in order to stabilise the surface exposed 
molecules. As mentioned above, lamotrigine is known to have poor flow properties and a 
tendency to agglomerate. Selecting these excipients, which bind well to the surfaces of the drug 
particles, will likely reduce this tendency to agglomerate and make the formulation more 
amenable to manufacturing processes. 
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Figure 10. SystSearch interaction fields for the impurity dichlorobenzoic acid on the major 
surfaces of lamotrigine. Each point represents an individual interaction between a 
dichlorobenzoic acid molecule and the lamotrigine surface. The points are coloured depending 
on the strength of the interaction. Points coloured blue represent the sites of most favourable 
interactions while red points represent the least favourable interactions. 
 
Figure 10 shows the interaction sites found for 2,3-dichlorobenzoic acid on the various major 
surfaces of lamotrigine. The depth and strength of the interaction points on the {110} and {11-
1} surfaces, and to a lesser extent the {200} surfaces, highlights the important role of the 
roughness of these surfaces in creating favourable adsorption sites. Contrast this to the much 
smoother {20-2} and {002} surfaces, where favourable sites within the surface are not found. 
By investigating the interactions of relevant molecules with the major particle surfaces of a 
material it is possible to gain a better understanding of how that material might interact with 
different media. When applied to lamotrigine, this approach enables rationalisation of the 
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drug’s interactions with an impurity, its low aqueous solubility, and the choice of excipients 
during formulation. 
 
Conclusions 
This work has shown how use of digital design approaches can be used to provide a thorough 
analysis of a particle’s properties. By combining this “Particle Informatics” workflow with key 
experimental measurements, a material’s industrially important characteristics such as 
solubility, tabletability, flow, and crystal growth behaviour can be understood. The knowledge 
gained from this “Particle Informatics” approach can be used to resolve key formulation and 
manufacturing decisions and can anticipate potential bottlenecks in pharmaceutical processes. 
Through a combination of computational and topological methods, we can better understand 
the particle properties of the drug lamotrigine. We have analysed its intrinsic intermolecular 
interactions, its mechanical properties, its morphology and its surface energy and chemistry, 
and used this information to rationalise several issues encountered during the formulation and 
manufacturing of this drug. 
We hope that by application of the “Particle Informatics” workflow at the earliest possible 
stage of pharmaceutical development, issues such as those encountered for lamotrigine can be 
anticipated and avoided, enabling drugs to be delivered faster and more efficiently. 
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Synopsis 
We introduce a combination of new and existing approaches to assess and predict particle 
properties intrinsic to the formulation and manufacture of pharmaceuticals. A novel workflow 
brings these approaches together to build on the knowledge gained from each step and explain 
how this knowledge can be combined to provide resolutions at decision points encountered 
during formulation design and manufacturing processes. 
 
